Cambridge Healthtech Institute’s 7th Annual

Adoptive Cell Therapy

Engineering the Second Generation of CAR Ts, TCRs, and TILs

August 11-12, 2020



Efforts to engineer CAR Ts, NKs, TCRs, and TILs with greater precision, safety profiles, and efficacy are leading to the second generation of improved adoptive cell therapies. With multiple engineered receptors already making preclinical impact, many biotech and pharma companies are preparing for the next wave of clinical trials. The end goal is still the same: improved patient outcomes. However, there remain technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management. Cambridge Healthtech Institute’s Seventh Annual Adoptive Cell Therapy conference focuses on the next steps needed to deliver CAR Ts, TCRs, and TILs into the clinic.

Preliminary Agenda

ADVANCES IN ADOPTIVE T CELL THERAPY

Targeting Tumor-Reactive T Cells for Adoptive Immunotherapy in Humans

Andrew Weinberg, PhD, Chief, Laboratory of Basic Immunology, Providence Health & Services; CSO, AgonOx

Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy

Michael Klichinsky, PharmD, PhD, Co-founder & Vice President, Discovery, Carisma Therapeutics

TruC-T Cells: Redefining T Cell Therapies for Cancer

Garry Menzel, PhD, President & CEO, TCR2 Therapeutics

Talk Title to be Announced

Andreas Bader, PhD, Senior Vice President, R&D, Triumvira

OFF-THE-SHELF, Allogeneic CELL THERAPY

Speakers to be Announced

GENETIC ENGINEERING FOR CELL THERAPY

Talk Title to be Announced

Christina Coughlin, MD, PhD, CMO, Rubius Therapeutics

 

GAMMA DELTA T CELLS

Speakers to be Announced

PLENARY KEYNOTE SESSION

PD-1 Antibodies Either as Monotherapy or Precision Medicine Informed Combinations are Transforming Cancer Care

Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Korean